A focused and patient centric approach to drug discovery and development drives all our activity.”
Early Oncology Development
It takes a special scientific mindset to participate in early drug development. You have to be curious and perseverant to explore new compounds, study them in depth and critically evaluate their promise as therapeutic agents.
Discovery scientists have to be prepared to efficiently test and critically evaluate many, many compounds knowing full well that while many may be scientifically promising, only a few will come to fruition.
Maximising early drug development potential – integrated cross-functional teams
At Janssen we know that our discovery efforts can only reach maximum potential in light of a bigger picture. That’s why we integrate our world-class development and commercialization capabilities with our discovery teams.
These integrated teams are organized within Disease Area Strongholds. These are areas of intense focus. Here we cultivate deep expertise. It’s where all of our early- and late-stage research, development and commercialization capabilities are strategically aligned against common goals and objectives.
Advanced discovery platforms and technology portfolio core strengths
This focused approach enables us to fully leverage our advanced discovery platforms and technology portfolio against clearly defined medical needs, therapeutic pathways and targets. We have core strengths and infrastructure in discovery, development, manufacturing and monoclonal antibody technologies. We are also leaders in the development and use of new biologics platforms.
Open collaboration model key to confronting the cancer challenge
We know that no one company, no single academic institution, can solve the challenge of cancer. Through our research partnerships we are bringing together the best scientific minds in industry and academia – wherever they may be, inside or outside our company – to confront the cancer challenge.
J&J innovation centres strong hub for external-internal cooperation
Similarly, our J&J Innovation Centres in London, Boston, San Francisco and Shanghai complement our internal expertise with external innovation. J&J launched these centres in 2013. They work globally with life science researchers and entrepreneurs to identify exciting early-stage technologies and to translate them into solutions for patients.
J&J supports entrepreneurs and scientists in regional hubs
Our Innovation Centres serve as regional hubs. J&J created them to access the best science and technology in each region. They also look to meet the needs of entrepreneurs and scientists developing important medical device and diagnostic technologies, consumer healthcare products, and pharmaceuticals.
The innovation centres have greatly enhanced our ability to source and develop innovative products. We have formed approximately 300 external collaborations and brought more than 500 companies into our incubators.